When was GIO Therapeutics founded?

GIO Therapeutics was founded in 2024.

Where is GIO Therapeutics located?

GIO Therapeutics is headquartered in Basel, Switzerland.

Who is the current CEO of GIO Therapeutics?

Xavier Leroy of GIO Therapeutics. They have also founded 1 company.

Is GIO Therapeutics a funded company?

GIO Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does GIO Therapeutics rank among its competitors?

GIO Therapeutics ranks 2693rd amongst 3250 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of GIO Therapeutics?

GIO Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

GIO Therapeutics - 2026 Company Profile, Team & Competitors

GIO Therapeutics is an unfunded company based in Basel (Switzerland), founded in 2024 by Xavier Leroy. It operates as a Developer of therapeutics to treat cancer and inflammatory diseases. GIO Therapeutics has not raised any funding yet. The company has 3250 active competitors, including 1119 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of therapeutics to treat cancer and inflammatory diseases. The company specializes in the development of G protein-coupled receptor-targeted pharmaceuticals to address complex challenges in oncology and inflammatory diseases.

Key Metrics

Founded Year

2024

Location

Basel, Switzerland

Stage

Unfunded

Ranked

2693^rd among 3250 active competitors

Similar Companies

BeiGene & 551 more

View GIO Therapeutics' full profile

GIO Therapeutics has not raised any funding rounds yet.

The founders of GIO Therapeutics is Xavier Leroy. Xavier Leroy is the CEO of GIO Therapeutics.

Here are the details of GIO Therapeutics' key team members:

Xavier Leroy: Co-Founder & CEO of GIO Therapeutics.
Contact Info: 1 email address

View details of GIO Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GIO Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of GIO Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
2693rd	GIO Therapeutics 2024, Basel (Switzerland), Unfunded	Developer of therapeutics to treat cancer and inflammatory diseases	-	-	23/100